Title

Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection.

Document Type

Article

Publication Date

4-1-2018

Publication Title

Drugs of today (Barcelona, Spain : 1998)

Abstract

Hepatitis C virus (HCV) is a significant public health burden worldwide, owing in large part to ineffective and poorly tolerated treatments. The antivirals have evolved over time to become more effective and better tolerated with cure rates increasing from an average of 50% to a complete virologic response. This article summarizes the latest Food and Drug Administration (FDA)-approved addition to combination treatment for patients with HCV, voxilaprevir plus sofosbuvir/velpatasvir.

Medical Subject Headings

Antiviral Agents; Carbamates; Drug Combinations; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Macrocyclic Compounds; Sofosbuvir; Sulfonamides; Treatment Outcome

PubMed ID

29869647

Volume

54

Issue

4

First Page

255

Last Page

268

Share

COinS